Daniel Erlanson

Dan Erlanson, Ph.D., is Frontier Medicines’ Senior Vice President of Innovation and Discovery. He is an expert in fragment-based and covalent drug discovery. Prior to Frontier, Dan co-founded Carmot Therapeutics, where he developed drug discovery technologies and led chemistry efforts that resulted in three clinical-stage molecules and partnerships with biotech companies including Amgen and Genentech. One of the molecules advanced by Amgen, LUMAKRAS™ (sotorasib), has received FDA approval.

Before Carmot, Dan spent a decade developing drug discovery technologies and leading various medicinal chemistry efforts in oncology, metabolic, and inflammatory diseases at Sunesis Pharmaceuticals, which he joined at the company’s inception.

Dan is an inventor on more than fifteen issued US patents, an author of more than 40 scientific publications, and co-editor of two books on fragment-based drug discovery (FBDD). Since 2008, he has served as an advisor to Stanford University’s SPARK Translational Research Program, which supports academics hoping to develop clinical products.

Dan was an NIH postdoctoral fellow with James A. Wells at Genentech. He earned his Ph.D. in Chemistry from Harvard University in the laboratory of Gregory L. Verdine, and his B.A. in Chemistry from Carleton College.